Prophylaxis and treatment of pulmonary embolism, and venous thrombosis and its extension; prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation and cardiac valve replacement; reduction of risk of death, recurrent MI, and thromboembolic events such as stroke or systemic embolism after MI.
PO, IV (Adults): 2.5–10 mg/day for 2–4 days; then adjust daily dose by results of prothrombin time or international normalized ratio (INR). Initiate therapy with lower doses in geriatric or debilitated patients.
PO, IV (Children > 1 month): Initial loading dose – 0.2 mg/kg (maximum dose: 10 mg) for 2–4 days then adjust daily dose by results of prothrombin time or international normalized ratio (INR), use 0.1 mg/kg if liver dysfunction is present. Maintenance dose range-0.05–0.34 mg/kg/day.
Pregnancy; hemorrhagic tendencies or blood dyscrasias; recent or contemplated surgery of the CNS, eye, or traumatic surgery resulting in large open surfaces; bleeding tendencies associated with active ulceration or overt bleeding of GI, GU, or respiratory tracts; cerebrovascular hemorrhage; cerebral or dissecting aorta aneurysms; pericarditis and pericardial effusions; bacterial endocarditis; threatened abortion, eclampsia, and preeclampsia; spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrolled bleeding; major regional, lumbar block anesthesia; malignant hypertension; inadequate laboratory facilities; unsupervised patients with senility; hypersensitivity to any component of the product.